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Abstract
Genome-wide association studies have identified 32 loci associated with body mass index (BMI),
a measure that does not allow distinguishing lean from fat mass. To identify adiposity loci, we
meta-analyzed associations between ~2.5 million SNPs and body fat percentage from 36,626
individuals, and followed up the 14 most significant (P<10−6) independent loci in 39,576
individuals. We confirmed the previously established adiposity locus in FTO (P=3×10−26), and
identified two new loci associated with body fat percentage, one near IRS1 (P=4×10−11) and one
near SPRY2 (P=3×10−8). Both loci harbour genes with a potential link to adipocyte physiology, of
which the locus near IRS1 shows an intriguing association pattern. The body-fat-decreasing allele
associates with decreased IRS1 expression and with an impaired metabolic profile, including
decreased subcutaneous-to-visceral fat ratio, increased insulin resistance, dyslipidemia, risk of
diabetes and coronary artery disease, and decreased adiponectin levels. Our findings provide new
insights into adiposity and insulin resistance.
Adiposity is a key risk factor for a number of common metabolic disorders, such as type 2
diabetes and cardiovascular disease1. Although the recent global increase in adiposity has
been driven by lifestyle changes, family and twin studies suggest that there is also a
substantial genetic component contributing to inter-individual variation in adiposity2. The
specific loci accounting for this variation remain largely unknown.
Recent genome-wide association studies (GWAS) have identified 32 common loci
associated with body mass index (BMI)3-8 - the most commonly used index of adiposity and
the diagnostic criterion for overweight and obesity1. These loci, however, account only for a
small fraction of the variation in BMI8. Although BMI is generally a good indicator of
adiposity and disease risk, it does not allow distinguishing between lean and fat body mass.
Using body fat percentage, a more accurate measure of body composition, may identify new
Kilpeläinen et al. Page 3
Nat Genet. Author manuscript; available in PMC 2012 January 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
loci more directly associated with adiposity. Therefore, we conducted a meta-analysis of 15
GWAS of body fat percentage, including altogether 36,626 individuals of white European
(n=29,069) and Indian-Asian (n=7,557) descent, and followed-up the most significant
findings in up to 39,576 European individuals.
RESULTS
Stage 1 genome-wide association meta-analysis of body fat percentage
We first performed a meta-analysis for the associations of body fat percentage with ~2.5
million genotyped or imputed SNPs from 15 studies, including up to 36,626 individuals of
white European (n=29,069) and Indian-Asian (n=7,557) descent (Online Methods,
Supplementary Figure 1). To identify genetic loci that may associate with body fat
percentage in European individuals only, we performed an additional meta-analysis of
individuals of European descent. Furthermore, meta-analyses were also performed in men
(nEuropean=13,281; nIndian-Asian=6,535) and women (nEuropean=15,789; nIndian-Asian=1,022)
separately to identify sex-specific associations with body fat percentage. Genetic variants in
the fat mass and obesity-associated (FTO) gene and near the insulin receptor substrate 1
(IRS1) gene showed genome-wide significance (P<5×10−8) at this stage (Table 1, Figure 1).
To confirm the loci near-IRS1 and FTO loci and to identify more adiposity loci, we took
forward 14 SNPs representing the 14 most significant and independent loci for which
association with body fat percentage reached a significance of P<10−6 in all individuals
combined, in Europeans, in men, or in women (Supplementary Table 1, Supplementary
Figure 2). Loci were considered independent when they were in low linkage disequilibrium
(r2<0.3) or were >1 Mb apart.
Stage 2 follow-up analyses identify three loci associated with body fat percentage
We examined the associations of the 14 SNPs with body fat percentage in up to 39,576
additional individuals of European descent from 11 studies (stage 2) (Online Methods,
Supplementary Table 2, Supplementary Figure 1). In a joint meta-analysis of stage 1 and
stage 2 results, three of the 14 SNPs reached genome-wide significance (P<5×10−8) for
association with body fat percentage (Table 1, Supplementary Table 3). We confirmed
associations for the SNP in FTO (chr16: rs8050136; Pall=3×10−26) and for the SNP near
IRS1 (chr2: rs2943650; Pall=4×10−11), which both reached genome-wide significance in
stage 1 and identified a third locus near the sprouty homolog 2 (SPRY2) gene (chr 13:
rs534870; PEuropeans =3×10−8 ). The near-SPRY2 locus showed association with body fat
percentage only in white Europeans and not in Indian Asians, whereas the effect sizes for
the near-IRS1 and in FTO loci were similar in meta-analyses of ‘Europeans only’ vs.
‘Europeans and Indian Asians combined’ (Table 1 and Supplementary Table 4). The
association of the near-IRS1 SNP with body fat percentage was significantly
(Psex-difference=0.02) more pronounced in men (P=3×10−11) than in women (P=9×10−3)
(Table 1 and Supplementary Table 3). While FTO is a well-established adiposity gene3,5, the
near-IRS1 and near-SPRY2 loci have not been previously implicated in adiposity. Therefore,
we focused our follow-up analyses on the near-IRS1 and near-SPRY2 loci to estimate their
impact on related metabolic traits and to gain insight into the potential functional roles of
these two new adiposity loci.
Influence of genetic variation near IRS1 on anthropometric and related metabolic traits and
its potential functional role
The rs2943650 SNP near IRS1 was associated with a 0.16% lower body fat percentage per
copy of the major allele. The effect was stronger in men than in women (beta = 0.20% and
0.06% per allele, respectively). Interestingly, despite the highly significant associations with
body fat percentage, we found no convincing evidence of association between the near-IRS1
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SNP and BMI (Pall=0.32, Pmen=0.16, Pwomen=0.79) or other obesity-related traits
(Supplementary Table 5). As BMI represents both fat and lean mass, whereas body fat
percentage is a measure of the relative proportion of these two tissues, our observation
suggests that the locus near IRS1 influences specifically adiposity, or alternatively,
influences fat mass and lean body mass in opposite directions.
The rs2943650 SNP is located 500 kb upstream of the IRS1 gene, an important mediator of
insulin and insulin-like growth factor-1 (IGF-1) signaling (Figure 2). Previous GWAS have
identified SNPs near IRS1, in high LD with rs2943650 (r2>0.8 in the HapMap CEU
population), to be associated with various metabolic traits9-11. Intriguingly, while we
observed the major allele of rs2943650 to be associated with lower body fat percentage,
prior work suggests that the major allele of rs2972146 (r2=0.95 with rs2943650) is
associated with higher triglycerides and lower HDL cholesterol9, the major allele of
rs2943641 (r2=1.00 with rs2943650) is associated with increased insulin resistance and risk
of type 2 diabetes10, and the major allele of rs2943634 (r2=0.83 with rs2943650) is
associated with increased risk of coronary artery disease11.
To better understand how genetic variation in the near-IRS1 locus is associated with both
lower body fat percentage and a more adverse metabolic profile, we performed a series of
focused follow-up analyses on the association of rs2943650 with lipid profiles, indices of
insulin sensitivity, fat distribution, and circulating levels of leptin and adiponectin in the
stage 2 studies that had all or some of these traits measured (Online Methods,
Supplementary Figure 1). These analyses confirmed that the body fat percentage decreasing
allele of rs2943650 is associated with higher triglycerides and lower HDL cholesterol levels,
and with increased insulin resistance, as indicated by the increased ratio of insulin area
under the curve (AUC) / glucose AUC, and decreased Matsuda12 and Gutt13 insulin
sensitivity indexes (Figure 3, Supplementary Table 6). Consistent with the sex difference
observed for the association of rs2943650 with body fat percentage, the associations with
HDL cholesterol and triglyceride levels were more pronounced in men (n=9,937 and
n=10,659, respectively) than in women (n=10,659 and n=10,848, respectively) (for sex-
differences P=0.027 and P=0.025, respectively) (Figure 3, Supplementary Table 6) whereas
associations with indices of insulin resistance were similar in both sexes.
To examine whether the association of the near-IRS1 locus with body fat percentage is
mediated through association with insulin sensitivity, we carried out an analysis for body fat
percentage adjusted for insulin sensitivity among 6,489 men of the METSIM (Metabolic
Syndrome in Men) study (Supplementary Figure 3). Similarly, to examine whether the
association of IRS1 with body fat percentage could explain association with insulin
sensitivity, we carried out an analysis for insulin sensitivity adjusted for body fat percentage.
While the effect size for the association of the rs2943650 (near IRS1) major allele with
reduced body fat percentage did not significantly (Pdifference=0.38) change after adjusting for
insulin sensitivity, the association with reduced insulin sensitivity became significantly
stronger when we adjusted for body fat percentage (Pdifference=0.035). These observations
suggest that the near-IRS1 locus may have a primary effect on body fat percentage and that
the association with decreased insulin sensitivity is partly mediated by changes in body fat
percentage, at least in men.
We next examined whether the concurrent association of the near-IRS1 locus with lower
body fat percentage and an adverse metabolic profile could be due to joint associations with
body fat distribution. Therefore, we determined associations of rs2943650 with abdominal
visceral and subcutaneous fat obtained by computerized tomography in GWAS meta-
analysis data of 10,557 individuals (personal communication with Caroline Fox). We found
that the near-IRS1 locus was associated with an adverse distribution of body fat in men, i.e.
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the body fat percentage decreasing allele reduced subcutaneous fat in men (P=1.8×10−3,
n=4,997) but not in women (P=0.063, n=5,560), whereas no association with visceral fat
was observed in either men (P=0.95) or in women (P=0.63). Most evidently, the body fat
decreasing allele of the locus near IRS1 was associated with a higher ratio of visceral
adipose tissue to subcutaneous adipose tissue in men (P=6.1×10−6) but not in women
(P=0.31). Our data thus suggest that the locus near IRS1 may associate with a reduced
storage of subcutaneous fat in men, which could contribute to the associations of this locus
with insulin resistance and dyslipidemia by leading to an ectopic deposition of lipids13.
Having demonstrated the association of the locus near IRS1 with the quantity and
distribution of body fat and with related metabolic traits, we aimed to determine whether this
locus is associated with measures of adipocyte function. Leptin and adiponectin are two
hormones (adipokines) produced exclusively in adipose tissue, which respond in a reciprocal
manner to changes in fat mass and insulin resistance. Higher levels of leptin and lower
levels of adiponectin correlate with increased body fat and insulin resistance14. Leptin data
was available for 4,641 individuals and adiponectin data for 9,769 individuals participating
in our stage 2 meta-analysis (Online Methods, Supplementary Figure 1). Interestingly, the
body fat percentage decreasing allele was associated with lower adiponectin levels in men
(P=6.1×10−6, n=8,681), which is in contrast to what we expected given the inverse
correlation between body fat percentage and adiponectin levels. No association with lower
adiponectin levels was observed in women (n=1,088), which was significantly different
from the association in men (Psex-difference=0.040) (Figure 3, Supplementary Table 6). The
association between the locus near IRS1 and leptin levels was not significant, which could
be due to low statistical power as the size of the sample available was small (Figure 3,
Supplementary Table 6). Intriguingly, recent studies in leptin-deficient (ob/ob) mice have
demonstrated that transgenic overexpression of adiponectin permits metabolically healthy
expansion of subcutaneous adipose tissue, preventing accumulation of lipids in liver and
retaining insulin sensitivity15. Vice versa, we speculate that the lower adiponectin levels,
seen in men with the fat percentage decreasing allele of the near-IRS1 locus, might be
associated with the lack of ability to expand subcutaneous adipose tissue, leading to a flux of
lipids into liver and increased insulin resistance through a lipotoxic mechanism16.
To examine whether the rs2943650 SNP modifies the function of the IRS1 gene, we studied
gene expression profiles within subcutaneous adipose tissue and blood from 604 Icelandic
individuals (the deCODE cohort)6,17, within liver (n=567), subcutaneous (n=610) and
omental (n=742) adipose tissue from patients who underwent bariatric surgery18, and within
normal cortical brain samples of 193 individuals of European descent19 (Online Methods).
We found that the body fat percentage decreasing allele is associated with lower IRS1
expression in subcutaneous and omental adipose tissue but not in liver, brain, or blood
(Supplementary Table 7 and Supplementary Figure 4). The association with reduced
expression in subcutaneous and omental adipose tissues seemed more pronounced in men
than in women. Previous studies have shown that the body fat percentage decreasing allele
of rs2943641 in the same locus (r2=1.0 with rs2943650) is associated with reduced
expression of IRS-1 protein and reduced insulin-induced phosphatidylinositol 3-OH kinase
activity in skeletal muscle10.
Finally, to determine if there is a sex difference in the adipose tissue expression of the IRS1
gene, we analyzed gene expression in isolated adipocytes from male and female mice. The
data showed that adipocytes from females express higher levels of IRS1 than adipocytes
from males in both visceral and subcutaneous fat depots (Supplementary Figure 5). We
followed up this finding in human adipose tissue, and found that the expression of IRS1 was
significantly greater in visceral adipose tissue from women (n=75) than in visceral fat from
men (n=26), whereas no sex difference in IRS1 expression was seen in subcutaneous adipose
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tissue (Supplementary Figure 6). The higher basal levels of IRS1 in female adipose tissue
could, at least in theory, buffer women against the modest impairment of IRS1 expression
associated with genetic variation near IRS1.
Influence of genetic variation near SPRY2 and its potential functional role
The rs534870 SNP which reached a P value of 3×10−8 in our meta-analysis of European
individuals only is located 54 kb downstream of the SPRY2 gene with no other genes nearby
(Figure 2). The body fat decreasing (i.e. major) allele of rs534870 was associated with
0.14% decrease in body fat percentage. Unlike for the near-IRS1 locus, the association was
similar in men and women (Pdiff=0.62), and no association was observed in Indian Asians
(Table 1). We found a modest association for rs534870 with BMI, body weight, and risk of
obesity in a meta-analysis of all stage 2 studies (Supplementary Table 8). There was no
association between near-SPRY2 and blood lipids, but we found a nominally significant
association between the body fat percentage decreasing allele and increased insulin
sensitivity measured with the Gutt insulin sensitivity index13 (Supplementary Table 8). The
association with Gutt index was not significant after adjustment for body fat percentage
(P=0.2). The body fat percentage decreasing allele of rs534870 was modestly associated
with decreased SPRY2 expression in whole blood. In contrast with the near-IRS1 locus, there
was no association between rs534870 and SPRY2 expression in adipose tissue, brain or liver
(Supplementary Table 7 and Supplementary Figure 4).
SPRY2 encodes a negative feedback regulator of the Ras/mitogen-activated protein kinase
pathway20. At the cellular level, overexpression of SPRY2 inhibits migration and
proliferation of a variety of cell types in response to serum and growth factors21-23. Recent
studies have identified SPRY1, a homolog of SPRY2, as a critical regulator of adipose tissue
differentiation in mice24. The loss of SPRY1 function resulted in a low bone mass and high
body fat phenotype.
Association of established BMI, waist circumference, and extreme obesity loci with body
fat percentage
Previous GWAS have examined BMI as an index of adiposity3-8, and the recent meta-
analysis by the GIANT (Genetic Investigation of Anthropometric Traits) Consortium
increased the total number of established BMI susceptibility loci to 328. The associations of
the 32 confirmed BMI loci with body fat percentage were all directionally consistent with
the previously established BMI associations (Binomial Sign Test P<0.0001), and
associations for 17 of these loci reached nominal statistical significance (Supplementary
Table 9). Our stage 1 sample size of 36,626 individuals was small compared to the GIANT
stage 1 meta-analysis of BMI, which included 123,865 individuals, and we had thus
insufficient power to confirm all 32 loci as body fat percentage loci. Furthermore, as BMI is
a composite trait of fat and lean mass, BMI loci may associate with BMI by increasing fat
mass, lean mass, or both. Disentangling whether the established BMI loci associate with
body fat percentage per se or with body mass overall will require larger sample sizes.
Other GWAS have identified three loci associated with waist circumference25,26 and five
loci associated with extreme obesity27,28. Similarly with BMI loci, the associations of these
eight loci with body fat percentage were directionally consistent with the previously
established associations (Binomial Sign Test P=0.008), and associations for one waist
circumference locus and two extreme obesity loci reached nominal significance
(Supplementary Table 9).
Apart from GWAS that examined traits related to overall adiposity, recent GWAS studies
have identified 14 loci associated with waist-to-hip ratio adjusted for BMI26,29, a measure of
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body fat distribution. We found no association between these WHR loci and increased body
fat percentage (Supplementary Table 9), which is consistent with the observation that these
14 loci are not or only very weakly associated with BMI and likely due to the fact that these
loci were identified after accounting for BMI in the analyses.
DISCUSSION
Using a two-stage genome-wide association meta-analysis including up to 76,150
individuals, we identified three loci convincingly associated with body fat percentage. While
FTO was previously established as an obesity-susceptibility locus3,5, the loci near IRS1 and
near SPRY2 have not previously been identified in the large-scale genome-wide association
studies for BMI8, waist circumference25,26, waist-to-hip ratio26,29 or extreme obesity27,28,
suggesting that these loci have a specific association with body fat percentage.
The locus near IRS1 is associated with lower body fat percentage in men; more specifically
with proportionally less subcutaneous compared to visceral fat. Of particular interest is the
pattern of association with other metabolic traits which was opposite to what would be
expected based on the known association between lower body fat percentage and improved
metabolic profile. In effect, the fat percentage decreasing allele of the locus near IRS1 was
associated with higher levels of insulin resistance, an adverse lipid profile and lower levels
of adiponectin in men. Furthermore, the fat percentage decreasing alleles of SNPs in the
locus near IRS1 have previously been associated with increased risk of type 2 diabetes10 and
coronary artery disease11.
We, and others10, demonstrated that genetic variation near IRS1 is associated with reduced
IRS1 expression in major insulin target tissues, including adipose tissue and muscle, which
may explain the association of this locus with increased whole-body insulin resistance and
risk of type 2 diabetes. The locus near IRS1 is one of the few loci thought to increase risk of
type 2 diabetes through an effect on insulin resistance, whereas other diabetes loci
predominantly associate with measures of impaired beta-cell function10,30. However, the
mechanisms linking the locus near IRS1 with type 2 diabetes may be more complex than
previously thought. Our data suggest that genetic variation near IRS1 may be associated with
a reduced ability to store subcutaneous fat, at least in men, which may partly explain the
association with whole-body insulin resistance and dyslipidemia. Adipose tissue insulin
sensitivity itself has little impact on whole body insulin sensitivity, which is largely
determined by the liver and muscle31. However, impaired ability of subcutaneous adipose
tissue to expand may disrupt insulin signaling in liver and muscle by leading to ectopic
deposition of lipids32. Such an indirect mechanism could exacerbate the intrinsic impairment
of IRS-1 signaling in muscle.
The association of the near-IRS1 locus with body fat percentage and with many of the
metabolic traits was more pronounced in men than in women. The mechanistic basis for this
sexual dimorphism is yet unclear, but may be related to the powerful drive to subcutaneous
adipogenesis in women compared to men, which may overcome a defect in IRS-1 function.
Men tend to deposit less subcutaneous and more visceral fat than women33, and IRS-1 may
thus have a stronger role in the regulation of subcutaneous fat in men. The association of the
near-IRS1 locus with the expression of IRS1 in subcutaneous adipose tissue was more
pronounced in men, indicating that there may be sex differences in the effects of the near-
IRS1 locus on gene function itself. We also demonstrated a sex difference in both mouse and
human adipose tissue expression of IRS1, with adipose tissue from females showing greater
IRS1 expression.
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IRS-1 function has been described in animal models. Knockout of IRS1 in mice leads to
hyperinsulinemia and mild-to-moderate insulin resistance despite a lean phenotype34,35.
IRS-236 and IRS-337,38 partly compensate for the lack of IRS-1. Knockout of IRS1 and IRS3
genes together leads to severe early-onset lipoatrophy with marked hyperglycemia,
hyperinsulinemia, and insulin resistance39. The gene encoding IRS-3 is lacking in the
humans, which may make humans more dependent on IRS-1. Data from cell lines of IRS1
knockout animals suggest that IRS1 is involved in adipocyte differentiation40,41. In IRS1
knockout mice, the ability of embryonic fibroblast cells to differentiate into adipocytes is
reduced by 60%40. Cells of knockout mice for both IRS1 and IRS2 are completely unable to
differentiate into adipocytes, and show a severe reduction in white adipose tissue soon after
birth40.
Our second new locus for body fat percentage, near-SPRY2, showed association only in
white Europeans, not in Indian Asians. Different from the near-IRS1 locus, the association
between the body fat percentage decreasing allele of near-SPRY2 and insulin resistance was
in the expected direction, i.e. this allele associated with higher insulin sensitivity and
adjustment for body fat percentage attenuated the association. Similarly with near-IRS140,41,
near-SPRY2 may play a role in the regulation of adipose tissue differentiation24. Different
from the GWAS of BMI, which have mainly established loci mechanistically linked with
central nervous system control of appetite and energy expenditure8, our meta-analysis of
body fat percentage thus indicates that loci harboring genes with potential links with
adipocyte physiology may also play important roles in the regulation of body adiposity.
Our stage 1 meta-analyses included individuals of European and of Indian Asian descent.
The Indian Asian individuals were mainly of north Indian descent (‘Ancestral north
Indians’, a western Eurasian population) and thus more closely related to Europeans, and, to
a lesser extent, to Asians (‘Ancestral south Indians’)42. Furthermore, the overall body fat
percentage of the Indian Asian sample did not differ from that of individuals of white
European descent in our study. However, despite some similarities, genetic differences
between European and Indian Asian populations remain, and as differences in body
composition between both ethnicities have been documented43, we also performed a stage 1
GWAS in Europeans only. Exclusion of the Indian Asians did not affect the associations
observed for the near-IRS1 locus, but it did for the near-SPRY2 locus. More specifically, the
near-IRS1 locus was associated with body fat percentage in individuals of European and of
Indian Asian descent at stage 1. The association for the near-SPRY2 locus, however, was
only seen in Europeans, whereas no association was seen in Indian Asians. These
observations illustrate the value of inclusion of the Indian Asian sample as stratified
analyses allow inferring the ethnic-specificity of the identified loci.
In summary, we identified a locus near the IRS1 gene that is associated with reduced body
fat percentage and adipose tissue IRS1 expression in men, but also with a combination of
adverse metabolic and disease risk traits, including lower levels of subcutaneous fat,
increased insulin resistance, dyslipidemia, decreased circulating levels of adiponectin, and
increased risk of diabetes and coronary artery disease. Furthermore, genetic variation in a
locus near SPRY2 associates with body fat percentage in individuals of European descent.
Our findings provide new insights into adiposity and insulin resistance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX
ONLINE METHODS
Study design
We designed a multi-stage study (Supplementary Figure 1) comprising a GWA meta-
analysis for body fat percentage (stage 1) of data of up to 36,626 individuals of European
(n=29,069) or Indian-Asian (n=7,557) descent from 15 studies, and selected 14 SNPs with P
values <1×10−6 for follow-up in stage 2. Stage 2 comprised up to 34,556 additional
European individuals from 11 studies. Body fat percentage in stage 1 and stage 2 cohorts
was measured either with bioimpedance analysis or dual energy x-ray absorptiometry
(DEXA), as described in the Supplementary Note. To explore the comparability of the
methods, we studied the correlation between body fat percentage obtained by DEXA and
bioimpedance in the Fenland study (n=2,535), in which both measurements were taken at
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the same time point. The Fenland study is a population-based cohort of white European men
and women between the age of 30-60 years (Supplementary Note - Table 3). The Pearson
correlation co-efficient showed that the DEXA and bioimpedance measurements of body fat
percentage are highly correlated (r=0.92). The correlation between body fat percentage with
BMI was moderate (r=0.62 measured by DEXA and r=0.58 measured by BIA, respectively).
Meta-analysis of stage 1 and stage 2 summary statistics identified three loci that reached
genome-wide significance (P<5×10−8) for the association with body fat percentage. Two of
these loci (near-IRS1 and near-SPRY2) had not been previously identified in genome-wide
association studies for BMI8, waist circumference25,26, waist-to-hip ratio26,29 or extreme
obesity27,28. Subsequently, we performed a series of focused follow-up analyses (stage 3) to
estimate the impact of these two new established body fat percentage loci and to explore
their potential functional roles.
Stage 1 genome-wide association meta-analysis of body fat percentage
Genotyping—The 15 studies included in the stage 1 meta-analysis were genotyped using
Affymetrix, Illumina, and Perlegen whole genome genotyping arrays (Supplementary Note).
To allow for meta-analysis across different marker sets, imputation of polymorphic HapMap
European CEU SNPs was performed using MACH45, IMPUTE46 or BIMBAM47
(Supplementary Note). Indian Asian genotype data in the Lolipop study was imputed using
pooled haplotypes from all three HapMap populations (CEU, YRI, JPT+CHB). Imputation
scores for the successful SNPs were slightly lower for Indian Asians than for Europeans.
The Indian Asian GWAS of men genotyped with Illumina 610 K array had an average r2-hat
of 0.942, whereas the GWAS from the GOOD study, genotyped with the same chip, had an
average r2-hat of 0.956. In the Indian-Asian GWAS genotyped with the Perlegen array,
average r2-hat was 0.751, whereas it was 0.851 in the European GWAS sample from the
same study, genotyped with the same chip. In previously published data48, comparisons of
imputed and experimentally derived genotypes in Indian-Asians yielded an estimated
imputation error rate of 2.86% per allele and an estimated average r2 of 89.8%
Association analysis with body fat percentage—Each study performed single
marker association analyses with body fat percentage using an additive genetic model
implemented in MACH45, Merlin49, SNPTEST46 or Plink50. Body fat percentage was
adjusted for age and age squared and inverse normally transformed to a mean of 0 and a
standard deviation of 1. Analyses were stratified by sex. To allow for relatedness in the
Framingham Heart, Amish HAPI Heart, Family Heart, and Erasmus Rucphen studies,
regression coefficients were estimated in the context of a variance component model that
modeled relatedness in men and women combined with sex as a covariate. In the Twins UK
study, only one twin was randomly selected for the analyses from monozygotic twin pairs,
whereas from dizygotic twin pairs, both twins were used for the analyses. Association
analyses accounted for the relatedness between dizygotic twin pairs.
Before performing meta-analyses on the genome-wide association data for the 15 studies,
SNPs with poor imputation quality scores (r2-hat <0.3 in MACH, proper_info <0.4 in
IMPUTE, or observed/expected dosage variance <0.3 in BIMBAM) were excluded for each
study. All individual GWAS were genomic control corrected before meta-analysis.
Individual study-specific genomic control values ranged from 0.979 to 1.052
(Supplementary Note).
Meta-analysis of stage 1 association results—Next, we performed the stage 1 meta-
analyses using the inverse variance method, which is based on beta-coefficients and standard
errors from each individual GWAS. The meta-analyses were performed for all individuals
Kilpeläinen et al. Page 11
Nat Genet. Author manuscript; available in PMC 2012 January 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
combined, for European individuals, for men, and for women using METAL (see URLs).
The genomic control values for the meta-analysed results were 1.074, 1.065, 1.052 and
1.040 in all individuals, European individuals, men, and women, respectively
(Supplementary Figure 7).
Selection of SNPs for follow-up—Fourteen SNPs, representing the 14 most significant
(<1×10−6) independent loci in all individuals, Europeans, men, or women (Table 1,
Supplementary Figure 2), were selected for replication analyses (stage 2). Loci were
considered independent when they were in low LD (r2<0.3) or were >1 Mb apart. SNPs
which had been genotyped in less than 50% of the samples and/or that had a minor allele
frequency <0.5% were excluded. For some loci, the SNP with the strongest association
could not be genotyped for technical reasons and was substituted by a proxy SNP that was in
high LD with it (r2>0.8) according to the HapMap CEU data. We tested the association of
these 14 SNPs in four de novo and seven in silico replication studies in stage 2.
Test for sex difference—The differences between the effect sizes in men and women for
the strongest signals were assessed with a t-test with additional correction for the correlation
between standard errors in men and women in the GWA data as follows: {t = (βmen −
βwomen)/[(se2men + se2women) − 2corr(βmen − βwomen)semensewomen]}.
Stage 2 follow up of 14 most significant loci
Samples and genotyping—Directly genotyped data for the 14 SNPs was available from
up to 22,485 adults of European ancestry from four studies (Supplementary Note). Samples
and SNPs that did not meet the quality control criteria defined by each individual study were
excluded. Minimum genotyping quality control criteria were defined as Hardy-Weinberg
Equilibrium P>10−6, call rate >90%, and concordance >99% in duplicate samples in each of
the follow-up studies. Association results were also obtained for the 14 most significant
SNPs from 10,713 individuals of European ancestry from seven GWAS that had not been
included in the stage 1 analyses (Supplementary Note). Studies included between 719 and
3,132 individuals and were genotyped using Affymetrix and Illumina genome-wide
genotyping arrays. Autosomal HapMap SNPs were imputed using either MACH45 or
IMPUTE46. SNPs with poor imputation quality scores from the in silico studies (r2.hat <0.3
in MACH or proper_info <0.4 in IMPUTE) were excluded.
Association analyses and meta-analysis—We tested the association between the 14
SNPs and body fat percentage in each in silico and de novo stage 2 studies separately as
described for the stage 1 studies. We subsequently performed a meta-analysis of beta-
coefficients and standard errors from the stage 2 studies using the inverse variance method.
Data was available for at least 31,705 individuals for 11 SNPs, except for three SNPs
(rs17149412 in FDFT1, rs7736910 near HTR1A and rs7738021 near MARCH3), for which
data was only available for ~24,400 individuals due to technical challenges relating to the
genotyping and imputation of these SNPs. Next, we performed a meta-analysis of the
summary statistics of the stage 1 and stage 2 meta-analyses using the inverse variance
method in METAL. Differences in effect sizes between men and women were assessed as in
stage 1.
Stage 3 follow-up of near-IRS1 and near-SPRY2
Association analyses of near-IRS1 and near-SPRY2 with anthropometric
traits, obesity, and overweight—The associations of the near-IRS1 and near-SPRY2
loci with BMI, body weight, height, risk of being obese (BMI ≥30 kg/m2), and risk of being
overweight (BMI ≥25 kg/m2) were tested in all stage 2 studies (Supplementary Figure 1,
Supplementary Note - Tables 4-8). Additional analyses for waist circumference, hip
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circumference, and waist-to-hip ratio were performed in three of the stage 2 studies (EPIC-
Norfolk, Fenland, and MRC Ely) (Supplementary Figure 1). The associations of the SNPs
with quantitative secondary traits (BMI, body weight, height, waist circumference, hip
circumference, and waist-to-hip ratio) were tested with linear regression. The associations
with overweight or obese status were assessed using logistic regression. All quantitative
traits were analysed as non-transformed data. All tests assumed an additive genetic model
and were stratified by sex, adjusting for age and age squared. Summary statistics (betas-
coefficients and standard errors) were meta-analysed using the inverse variance method of
METAL (see URLs).
Evidence for the association of the near-IRS1 locus with subcutaneous and visceral fat,
obtained by computerized tomography from 10,557 individuals, was extracted from another
GWAS meta-analysis (personal communication with Caroline Fox).
Association analyses of near-IRS1 and near-SPRY2 with blood lipids—
Associations of the near-IRS1 and near-SPRY2 loci with blood levels of HDL cholesterol,
triglycerides, and LDL cholesterol were examined in three of the stage 2 studies, including
EPIC-Norfolk, Fenland, and MRC Ely (Supplementary Figure 1). In the EPIC-Norfolk
Study, HDL-cholesterol and triglycerides were measured from non-fasting blood whereas
fasting blood samples were available in the MRC Ely and Fenland studies. The
concentration of LDL cholesterol was calculated using the Friedewald formula in all three
studies. The associations of the SNPs with lipid levels were tested with linear regression in
men and women separately, assuming an additive genetic model and adjusting for age, age
squared, and the use of lipid lowering medication. An inverse normal transformation for
lipid levels was performed in men and women separately before the analyses. Summary
statistics (beta-coefficients and standard errors) were pooled using the inverse variance
meta-analysis method of METAL (see URLs).
Association analyses of near-IRS1 with insulin sensitivity traits—The
associations of the near-IRS1 locus with insulin sensitivity traits [M/I ratio, i.e. glucose
infused (M) derived by the circulating insulin concentration (I); insulin area under the curve
(AUC) / glucose AUC ratio; Matsuda insulin sensitivity index12; Gutt insulin sensitivity
index13) were examined in five studies (METSIM, MRC Ely, RISC, ULSAM, and
Whitehall II), of which three (RISC, ULSAM, and Whitehall II) were not part of our stage 2
meta-analysis of body fat percentage (Supplementary Figure 1). The RISC and ULSAM
studies had data from both euglycemic-hyperinsulinemic clamps and oral glucose tolerance
tests (OGTT), whereas the METSIM, MRC Ely, and Whitehall II studies had OGTT data
only. The M/I ratios were thus only available from the RISC and ULSAM studies, whereas
the three other insulin sensitivity traits were available from all five cohorts. The samples and
assays used for the measurement of circulating levels of glucose and insulin are shown in
Supplementary Note - Table 9. Insulin AUC / Glucose AUC ratio and Matsuda and Gutt
insulin sensitivity indexes were calculated using data from all available measurement time
points. As the Whitehall II cohort had only two measurement time points available, the
results from Whitehall II were not included in our meta-analysis of the association between
the near IRS1 locus and insulin AUC / glucose AUC ratio.
Individuals were excluded from the analyses on insulin sensitivity traits if they had self-
reported or physician diagnosed diabetes or were using oral antidiabetic drugs or insulin.
The associations of the SNPs near IRS1 with insulin sensitivity traits were tested with linear
regression in men and women separately, assuming an additive genetic model and adjusting
for age and squared. All insulin sensitivity traits were inverse normally transformed in men
and women separately before the analyses. Summary statistics (beta-coefficients and
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standard errors) were pooled using the inverse variance meta-analysis method of METAL
(see URLs).
Association analyses of near-IRS1 with leptin and adiponectin—The associations
of the near-IRS1 locus with circulating levels of adiponectin were examined in three studies
participating in our stage 2 meta-analysis (METSIM, MRC Ely, MrOS Sweden) and in the
RISC study (Supplementary Note - Tables 4-8). The samples and assays used for the
measurement of leptin and adiponectin are listed in Supplementary Note - Table 9. The
associations were tested using linear regression in men and women separately, assuming an
additive genetic model and adjusting for age and age squared. Analyses on leptin levels in
the MrOS Study were additionally adjusted for study centre. Leptin and adiponectin levels
were inverse normal transformed in men and women separately before the analyses.
Summary statistics (beta-coefficients and standard errors) were pooled with the inverse
variance meta-analysis method of METAL (see URLs).
eQTL analyses for near-IRS1 and near-SPRY2—The gene expression analyses for
the near-IRS1 and near-SPRY2 loci in subcutaneous adipose tissue and in whole blood from
Icelandic individuals were carried out as described in detail previously (GEO database:
GSE7965 and GPL3991)6,17. In brief, 603 individuals with adipose tissue samples and 745
blood samples were genotyped with the Illumina 317K or 370K chip. The RNA samples
were hybridized to a single custom-made human array containing 23,720 unique
oligonucleotide probes. Association was tested between the SNPs and the mean logarithm
(log10) expression ratio (MLR) adjusting for age, sex, and age*sex, as well as differential
cell count in the blood analyses, assuming an additive genetic model and accounting for
familial relatedness.
The gene expression analyses for the near-IRS1 and near-SPRY2 loci in liver, subcutaneous
and omental fat tissue from American patients who underwent bariatric surgery have been
described in detail previously18. In brief, liver (n=567), subcutaneous (n=610) and omental
(n=742) fat tissue were obtained. RNA was extracted and hybridized to a custom Agilent
44,000 feature microarray composed of 39,280 oligonucleotide probes targeting transcripts
representing 34,266 known and predicted genes. All patients were genotyped on the
Illumina 650Y SNP genotyping arrays. Cis-associations between each SNP and the adjusted
gene expression data were tested with linear regression, adjusting for age, race, gender, and
surgery year.
The eQTL analyses in cortical tissue have also been described in detail previously (GEO
database: GSE8919)19. In brief, DNA and RNA of neuropathologically normal cortical brain
samples of 193 individuals (mean age 81 years, range 65-100 years) of European descent
were isolated. DNA was genotyped using the Affymetrix Gene-Chip Human Mapping 500K
Array Set and genotypes were imputed using the data from the Phase II HapMap CEU
population. RNA expression was assessed with the Illumina Human Refseq-8 Expression
BeadChip system. Cis-association analyses assumed an additive model and were adjusted
for sex and age at death.
Analyses for IRS1 expression in mouse adipocytes—Mice were housed in a
temperature-controlled environment in groups of two to five at 22°C-24°C using a 12 h
light/12 h dark cycle. Some cohorts were singly housed to measure food intake. The mice
were fed standard chow (#2916, Harlan-Teklad, Madison, WI) and water was provided ad
libitum. Care of all animals and procedures were approved by the UT Southwestern Medical
Center.
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The fractionation of SV cells and adipocytes was performed as described previously51 with
slight modifications. Briefly, SV cells were isolated from pooled white adipose depots
[(inguinal, perigonadal, retroperitoneal, interscapular (the white adipose tissue juxtaposed to
the interscapular brown adipose tissue)] that were explanted and minced into fine pieces
(2-5mm2). The adipose pieces were then digested in adipocyte isolation buffer (100mM
HEPES pH7.4, 120mM NaCl, 50mM KCl, 5mM glucose, 1mM CaCl2, 1.5% BSA)
containing 1mg/ml collagenase at 37°C with constant slow shaking (~120rpm) for 2 hours.
During the digestion period, the suspension was triturated several times through a pipet to
dissociate the clumps. The suspension was then passed through an 80mm mesh to remove
undigested clumps and debris. The effluent was centrifuged at 500xg for 10 minutes and the
pellet washed once in 5ml PBS. To isolate floated adipocytes, the just-described
collagenase-treated mixture was passed through a 210mm mesh, centrifuged at 500xg for 10
minutes and floated adipocytes collected from the top. Adipocyte gene expression was
analyzed by qPCR.
Analyses for IRS1 expression in human adipose tissue—We analyzed 108 (from
29 men and 79 women) subcutaneous and 105 visceral (from 29 men and 76 women)
adipose tissue samples from participants with a body mass index (BMI) within 20 and 68 kg/
m2, who were recruited at the Endocrinology Service of the Hospital Universitari Dr. Josep
Trueta (Girona, Spain). All subjects were of Caucasian origin and reported that their body
weight had been stable for at least three months before the study. Individuals with liver and
renal diseases were excluded. All subjects gave written informed consent. Adipose tissue
samples were obtained from subcutaneous and visceral fat depots during elective surgical
procedures (cholecystectomy, surgery of abdominal hernia and gastric by-pass surgery). All
samples were washed, fragmented and immediately flash-frozen in liquid nitrogen before
storing at −80°C.
RNA was prepared from the adipose tissue samples using RNeasy Lipid Tissue Mini Kit
(QIAgen, Izasa SA, Barcelona, Spain). The integrity of each RNA sample was checked by
Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). Total RNA was
quantified by a spectrophotometer (GeneQuant, GE Health Care, Piscataway, NJ, USA) and
reverse transcribed to cDNA using High Capacity cDNA Archive Kit (Applied Biosystems
Inc., Madrid, Spain) according to the manufacturer’s instructions.
Gene expression was assessed by real time PCR using an ABI Prism 7000 Sequence
Detection System (Applied Biosystems Inc, Madrid, Spain) and TaqMan. The following
commercially available and pre-validated TaqMan primer/probe sets were used: endogenous
control PPIA (4333763, cyclophilin A, Applied Biosystems Inc., Madrid, Spain) and target
gene Insulin Receptor Substrate 1 (IRS1, Hs00178563_m1, Applied Biosystems Inc,
Madrid, Spain). The RT-PCR TaqMan reaction was performed in a final volume of 25μl.
The cycle program consisted of an initial denaturing of 10 min at 95°C, 40 cycles of 15 sec
denaturizing phase at 95°C, and 1 min annealing and extension phase at 60°C. A threshold
cycle (Ct value) was obtained for each amplification curve and a ΔCt value was first
calculated by subtracting the Ct value for human Cyclophilin A (PPIA) RNA from the Ct
value for each sample. Fold changes relative to the endogenous control were then
determined by calculating 2−ΔCt. The gene expression results are thus expressed as an
expression ratio relative to PPIA gene expression according to manufacturers’ guidelines.
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Figure 1.
Manhattan plot showing the significance of association with body fat percentage for all
SNPs in the stage 1 meta-analysis of all individuals (n=36,626). SNPs are plotted on the x-
axis according to their position on each chromosome against association with body fat
percentage on the y-axis (shown as −log10 P-value). The loci highlighted in blue are the 11
loci that reached an association P value < 10−6 in the stage 1 meta-analysis of all
individuals, Europeans, men, or women, and were taken forward for follow-up analyses, but
did not achieve genome-wide significance (P < 5 × 10−8) in the meta-analyses combining
GWAS and follow-up data. The three loci coloured in red are those that reached genome-
wide significant association (P < 5 × 10−8) in the meta-analyses combining GWAS and
follow-up data.
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Figure 2.
Regional plot of the loci near IRS1, near SPRY2, and in FTO that reached genome-wide
significant evidence for association with body fat percentage. The plotted data for the near-
SPRY2 locus are from the meta-analysis of individuals of European descent only, and the
data for the near-IRS1 and FTO loci are from the meta-analysis of all individuals. The
rs2943650 (near-IRS1), rs534870 (near-SPRY2), and rs8050136 (FTO) SNPs which showed
the strongest association with body fat percentage are indicated. For the near-IRS1 locus, the
rs2972146, rs2943641, and rs2943634 SNPs, which have been associated with blood levels
of HDL cholesterol and triglycerides9, risk of type 2 diabetes10 and risk of coronary artery
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disease11, respectively, in meta-analyses of genome-wide association studies are also
indicated. The plot was generated using LocusZoom44 (see URLs).
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Figure 3.
Association of the body fat percentage decreasing (T) allele of rs2943650 near IRS1 with
blood lipids, insulin sensitivity traits, leptin and adiponectin. The error bars indicate 95%
confidence intervals. All traits were inverse normally transformed to approximate normality
(mean = 0, sd = 1) in men and women separately. All models were adjusted for age and age
squared. The numeric values for the associations are presented in Supplementary Table 6. A
significant difference between men and women was found for the levels of HDL cholesterol
(P = 0.027), triglycerides (P = 0.025), and adiponectin (P = 0.040). InsAUC / GluAUC,
insulin area under the curve (AUC) / glucose AUC ratio.
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